QuadraMed Announces General Availability of Newest Revenue Cycle Management Release and Launches New HIM Workflow Solution

RESTON, Va.--(BUSINESS WIRE)--QuadraMed® Corporation (NASDAQ:QDHC) announced the general availability of Affinity® Revenue Cycle Management M8 release and introduced Quantim® Health Information (HIM) Workflow at the Healthcare Financial Management Association’s Annual National Institute Conference (ANI), Booth # 1042, June 14-17, at the Washington State Convention and Trade Center in Seattle.

“Using our enterprise scheduling solutions, providers will be able to verify medical necessity up front and set up automated call-back reminders for future appointments, as well as other time-saving functionalities.”

At ANI, QuadraMed will demonstrate how the Affinity Revenue Cycle Management system is integrated with the Quantim HIM suite. The enhanced integration will provide coders with a comprehensive view of encounters including “charge-based” codes to support real-time, interactive application of compliance edits that improve accuracy. QuadraMed has also enhanced the integration between Affinity Revenue Cycle Management and QuadraMed Enterprise Scheduling™ (QES).

“The new release and integration of the Affinity Revenue Cycle Management with the Quantim HIM suite and QES provides healthcare organizations with robust tools to maximize patient throughput, prevent costly claims denials, increase revenue, and expand clinician and employee satisfaction throughout the enterprise,” said Chris Callahan, QuadraMed's vice president of product strategy. “Using our enterprise scheduling solutions, providers will be able to verify medical necessity up front and set up automated call-back reminders for future appointments, as well as other time-saving functionalities.”

The comprehensive integration between Affinity Revenue Cycle Management and both the QES and Quantim HIM solutions helps users to operate more efficiently and cost-effectively, and to achieve the following benefits:

• Increased productivity with the ability to select a visit and quickly access the appropriate Affinity Revenue Cycle Management procedure and then return to the user’s original starting point in QES.
• Greater efficiencies with immediate access to patient appointment information via Affinity Revenue Cycle Management.
• Accelerated claims submissions and reimbursement processes.

QuadraMed will also demonstrate Quantim HIM Workflow, which is planned for general availability this year. Quantim HIM Workflow automates distribution and allocation of coding assignments, and allows organizations to measure and monitor coder productivity.

“We listened to the needs of our current clients and developed the next generation of integration for our product suites. This seamless exchange of data expedites access to patient information while producing significant benefits in workflow effectiveness, improved patient satisfaction and greater return on investment,” Callahan added.

About QuadraMed Corporation

QuadraMed Corporation advances the success of healthcare organizations through IT solutions that leverage quality care into positive financial outcomes. QuadraMed provides real world solutions that help healthcare professionals deliver outstanding patient care efficiently and cost effectively. Behind the Company’s products and services is a staff of 600 professionals whose experience and dedication have earned QuadraMed the trust and loyalty of clients at over 2,000 healthcare provider facilities. For more information about QuadraMed, visit http://www.quadramed.com.

Cautionary Statement on Risks Associated with QuadraMed Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 by QuadraMed that are subject to risks and uncertainties. The words "believe," "expect," "anticipate," "intend," "plan," "estimate," "may," "should," "could," and similar expressions are intended to identify such statements. Forward-looking statements are not guarantees of future performance and are to be interpreted only as of the date on which they are made. QuadraMed undertakes no obligation to update or revise any forward-looking statement except as required by law. QuadraMed advises investors that it discusses risk factors and uncertainties that could cause QuadraMed’s actual results to differ from forward-looking statements in its periodic reports filed with the Securities and Exchange Commission ("SEC"). QuadraMed’s SEC filings can be accessed through the Investor Relations section of our website, www.quadramed.com, or through the SEC’s EDGAR Database at www.sec.gov (QuadraMed has EDGAR CIK No. 0001018833).

QuadraMed is a registered trademark of QuadraMed Corporation. All other trademarks are the property of their respective holders.